We are live on ! Find out more
VINC

Vincerx Pharma, Inc. Common Stock
VINC

Delisted

VINC was delisted on the 22nd of April, 2025.

Back to rankings

9 hedge funds and large institutions have $8.05M invested in Vincerx Pharma, Inc. Common Stock in 2020 Q2 according to their latest regulatory filings, with 9 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
9
Holders Change
+9
Holders Change %
–
% of All Funds
0.18%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
–
Reduced
–
Closed
–
Calls
$167K
Puts
–
Net Calls
+$167K
Net Calls Change
+$167K

Top Buyers

Rank Fund Capital Flow
1
BFM
Boothbay Fund Management
New York
+$2.57M
2
MIM
Monashee Investment Management
Massachusetts
+$1.98M
3
PAMP
Polar Asset Management Partners
Ontario, Canada
+$1.58M
4
WRBC
W.R. Berkley Corp
Connecticut
+$443K
5
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
+$396K

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
BFM
1
Boothbay Fund Management
New York
$2.68M +$2.57M +13,000 New
MIM
2
Monashee Investment Management
Massachusetts
$1.99M +$1.98M +10,000 New
PAMP
3
Polar Asset Management Partners
Ontario, Canada
$1.59M +$1.58M +8,000 New
WRBC
4
W.R. Berkley Corp
Connecticut
$443K +$443K +2,236 New
Hudson Bay Capital Management
5
Hudson Bay Capital Management
Connecticut
$398K +$396K +2,000 New
RCM
6
Radcliffe Capital Management
Pennsylvania
$333K +$320K +1,617 New
PMAM
7
Picton Mahoney Asset Management
Ontario, Canada
$276K +$248K +1,250 New
BCM
8
Basso Capital Management
Connecticut
$250K +$248K +1,254 New
GCL
9
Glazer Capital LLC
New York
$89K +$89.1K +450 New

VINC Hedge Fund Activity: Q2 2020 in Review

9 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Vincerx Pharma, Inc. Common Stock (VINC) for Q2 2020, worth a combined $8.05M.

Buyers outnumbered sellers: 9 funds opened new VINC positions and 0 closed out — a net gain of 9 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Boothbay Fund Management, opening a new position worth an estimated $2.57M.

  • 9 institutional investors held Vincerx Pharma, Inc. Common Stock (VINC) as of Q2 2020, up from 0 in Q1 2020.
  • Funds reported $8.05M of Vincerx Pharma, Inc. Common Stock stock for Q2 2020.
  • 9 funds opened new Vincerx Pharma, Inc. Common Stock positions in Q2 2020 and 0 closed out, a net change of +9 holders.
  • The largest Vincerx Pharma, Inc. Common Stock buyer in Q2 2020 was Boothbay Fund Management, an estimated $2.57M added.

Based on aggregated 13F filings for Q2 2020.